Publications by authors named "C Aldieri"
Article Synopsis
- - Cefiderocol, a new antibiotic, is effective against carbapenem-resistant Gram-negative bacteria but lacks real-world usage data concerning therapy types and patient demographics.
- - A study of 200 cases found that cefiderocol was primarily used as targeted therapy (72.5%) rather than empirical (27.5%) and was administered equally as monotherapy (50.5%) and in combination (49.5%).
- - The findings highlight that specific patient histories, like previous infections and conditions, influence the choice between monotherapy and combination therapy, emphasizing the need for better guidelines and further studies on treatment efficacy.
Article Synopsis
- The study looked at how carbapenem resistance in a type of bacteria called Klebsiella pneumoniae affects how many people survive after getting a blood infection.
- Out of 426 patients, 25% had a more dangerous version of the bacteria, and those patients had higher death rates compared to those with a less resistant version.
- The research showed that the type of treatment given didn't really change the survival chances, suggesting that in certain areas, the treatment might be good enough for both types of bacteria.
Article Synopsis
- This study investigated the relationship between different types of respiratory support and the risk of barotrauma in COVID-19 patients during hospital stays from March 2020 to February 2021.
- It found that invasive mechanical ventilation and non-invasive ventilation (C-PAP/PSV) significantly increased the risk of barotrauma compared to conventional oxygen therapy, while High Flow Nasal Oxygen (HFNO) did not.
- The occurrence of barotrauma was low (1.00%) but was associated with older age, immunosuppression, and a higher risk of in-hospital death.
Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial.
BMC Infect Dis
November 2022
Background: The efficacy of early treatment with convalescent plasma in patients with COVID-19 is debated. Nothing is known about the potential effect of other plasma components other than anti-SARS-CoV-2 antibodies.
Methods: To determine whether convalescent or standard plasma would improve outcomes for adults in early phase of Covid19 respiratory impairment we designed this randomized, three-arms, clinical trial (PLACO COVID) blinded on interventional arms that was conducted from June 2020 to August 2021.
carbapenemase–producing (KPC) has been endemic in Italy since 2013. In a multicenter cohort study, we investigated various aspects of KPC among patients, including 15-day mortality rates and delays in adequate therapy. Most (77%) KPC strains were sequence type (ST) ST512 or ST307.
View Article and Find Full Text PDF